Literature DB >> 7955772

Desflurane clinical pharmacokinetics and pharmacodynamics.

J E Caldwell1.   

Abstract

Desflurane is a new volatile anaesthetic agent, with qualitative physiological and pharmacological effects similar to those of previously available drugs of this type. The feature that sets desflurane apart from other halogenated, volatile anaesthetics is its low solubility in blood and body tissues. Therefore, its uptake, distribution and elimination are more rapid than those for similar drugs. Desflurane undergoes negligible metabolism, and should have a low potential for producing toxic effects. Because it has a high vapour pressure desflurane needs a special delivery system, a heated, pressurised vaporizer. Its low solubility gives it the ability to produce rapid alterations in depth of anaesthesia and rapid emergence and recovery from anaesthesia.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7955772     DOI: 10.2165/00003088-199427010-00002

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN: 0312-5963            Impact factor:   6.447


  104 in total

1.  A comparison of desflurane and isoflurane in patients undergoing coronary artery surgery.

Authors:  I R Thomson; J B Bowering; R J Hudson; M A Frais; M Rosenbloom
Journal:  Anesthesiology       Date:  1991-11       Impact factor: 7.892

2.  The blood/gas solubilities of sevoflurane, isoflurane, halothane, and serum constituent concentrations in neonates and adults.

Authors:  S Malviya; J Lerman
Journal:  Anesthesiology       Date:  1990-05       Impact factor: 7.892

3.  Epinephrine-induced premature ventricular contractions and changes in arterial blood pressure and heart rate during I-653, isoflurane, and halothane anesthesia in swine.

Authors:  R B Weiskopf; E I Eger; M A Holmes; I J Rampil; B Johnson; J G Brown; N Yasuda; A G Targ
Journal:  Anesthesiology       Date:  1989-02       Impact factor: 7.892

4.  The new Tec6 desflurane vaporizer.

Authors:  J J Andrews; R V Johnston
Journal:  Anesth Analg       Date:  1993-06       Impact factor: 5.108

5.  Cerebral uptake and elimination of desflurane, isoflurane, and halothane from rabbit brain: an in vivo NMR study.

Authors:  S H Lockhart; Y Cohen; N Yasuda; B Freire; S Taheri; L Litt; E I Eger
Journal:  Anesthesiology       Date:  1991-03       Impact factor: 7.892

6.  Effects of clinically effective concentrations of halothane on adrenergic and cholinergic synapses in rat brain in vitro.

Authors:  C W Bazil; K P Minneman
Journal:  J Pharmacol Exp Ther       Date:  1989-01       Impact factor: 4.030

7.  Elderly patients recover more rapidly from desflurane than from isoflurane anesthesia.

Authors:  J A Bennett; N Lingaraju; J C Horrow; T McElrath; M M Keykhah
Journal:  J Clin Anesth       Date:  1992 Sep-Oct       Impact factor: 9.452

8.  Inhibition of plasma membrane Ca(2+)-ATPase activity by volatile anesthetics.

Authors:  D Kosk-Kosicka; G Roszczynska
Journal:  Anesthesiology       Date:  1993-10       Impact factor: 7.892

9.  Pharmacokinetics of inhaled anesthetics in humans: measurements during and after the simultaneous administration of enflurane, halothane, isoflurane, methoxyflurane, and nitrous oxide.

Authors:  R L Carpenter; E I Eger; B H Johnson; J D Unadkat; L B Sheiner
Journal:  Anesth Analg       Date:  1986-06       Impact factor: 5.108

10.  Isoflurane anesthesia and pressure antagonism in mice.

Authors:  D W Kent; M J Halsey; E I Eger; B Kent
Journal:  Anesth Analg       Date:  1977 Jan-Feb       Impact factor: 5.108

View more
  2 in total

Review 1.  Desflurane. A review of its pharmacodynamic and pharmacokinetic properties and its efficacy in general anaesthesia.

Authors:  S S Patel; K L Goa
Journal:  Drugs       Date:  1995-10       Impact factor: 9.546

2.  Hyperventilation accelerates the rise of arterial blood concentrations of desflurane in gynecologic patients.

Authors:  Chih-Cherng Lu; Tso-Chou Lin; Che-Hao Hsu; Mu-Hsien Yu; Ta-Liang Chen; Ruei-Ming Chen; Chih-Hung Ku; Shung-Tai Ho
Journal:  Clinics (Sao Paulo)       Date:  2012-09       Impact factor: 2.365

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.